Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 16148943 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Koo SH, et al. (2005) The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 437, 1109-11 16148943
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S133-p - CREB (mouse)
Orthologous residues
CREB (human): S133‑p, CREB iso2 (human): S119‑p, CREB (mouse): S133‑p, CREB (rat): S133‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  hepatocyte-liver
 Cellular systems studied:  primary cultured cells
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
glucagon increase
insulin increase

S171-p - TORC2 (mouse)
Orthologous residues
TORC2 (human): S171‑p, TORC2 (mouse): S171‑p, TORC2 (rat): S171‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  hepatocyte-liver
 Cellular systems studied:  primary cultured cells
 Species studied:  rat
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE AMPKA1 (rat)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
glucagon decrease initial decrease at 10 min followed by large increase by 3 hr
cycloheximide glucagon inhibit treatment-induced increase CHX pretreatment blocked delayed increase
insulin increase
glucagon SIK (human) increase Sik1 siRNA decreases
forskolin decrease
AICAR increase
forskolin AICAR decrease some decrease
Downstream Regulation
 Effect of modification (function):  activity, inhibited
 Effect of modification (process):  transcription, altered


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.